Oncology

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

A new strategic alliance between a pharma giant and a leading non-profit is deploying a $20M plan to close the deadly prostate cancer survival gap.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

At HLTH Europe, Saudi Arabia's KFSH revealed more than just a radiology AI. It unveiled a full ecosystem, proving how integrated tech transforms patient care.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.